Dyne Therapeutics, Inc.

DYNSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1818794

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$210.8M	$142.8M	$142.8M	$121.3M	$45.2M
Operating Expenses	$242.2M	$171.0M	$171.0M	$150.0M	$58.6M
Operating Income (Loss)	-$242.2M	-$171.0M	-$171.0M	-$150.0M	-$58.6M
Other Nonoperating Income (Expense)	$6.2M	$2.9M	$2.9M	$734.0K	-$790.0K
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$235.9M	-$168.1M	-$168.1M	-$149.3M	-$59.4M
Earnings Per Share, Basic	-$3.95	-$3.23	-$3.23	-$2.93	—
Earnings Per Share, Diluted	-$3.95	-$3.23	-$3.23	-$2.93	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$691.2M	$165.1M	$306.3M	$425.7M	$353.3M
Assets, Current	$659.3M	$129.4M	$265.6M	$382.4M	$349.1M
Cash and Cash Equivalents, at Carrying Value	$435.4M	$121.6M	$172.1M	$200.8M	$300.9M
Liabilities	$61.4M	$73.8M	$54.0M	$57.5M	$11.0M
Liabilities, Current	$42.3M	$51.1M	$28.1M	$28.7M	$11.0M
Long-term Debt	$0.00	—	—	—	—
Accounts Payable, Current	$6.6M	$22.9M	$5.3M	$4.0M	$3.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$188.2M	-$153.6M	-$153.6M	-$119.6M	-$46.5M
Net Cash Provided by (Used in) Investing Activities	$83.3M	$87.2M	$87.2M	-$137.9M	-$45.7M
Net Cash Provided by (Used in) Financing Activities	$54.3M	$37.4M	$37.4M	$157.8M	$380.7M
Payments to Acquire Property, Plant, and Equipment	$729.0K	$3.1M	$3.1M	$3.6M	$1.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)